Repositório Institucional - Unifesp :: Navegando por Palavras-chave "Tamoxifen"

Navegando por Palavras-chave "Tamoxifen"

Agora exibindo 1 - 20 de 23

Somente Metadadados
Analysis of the ki-67 index in the vaginal epithelium of castrated rats treated with tamoxifen
(Hospital clinicas, univ sao paulo, 2016) Nery-Aguiar, Afif Rieth; Aguiar, Yousef Qathaf; Conde Junior, Airton Mendes; Alencar, Airlane Pereira; Tavares, Cleciton Braga; Lopes-Costa, Pedro Vitor; Nazario, Afonso Celso [UNIFESP]; da Silva, Benedito Borges
OBJECTIVES: Vaginal atrophy and breast cancer are common conditions in postmenopausal women and tamoxifen is the standard endocrine treatment for hormone-sensitive tumors. The present study aimed to assess the effect of tamoxifen on Ki-67 protein expression in the vaginal epithelium of castrated rats. MATERIAL AND METHODS: Forty Wistar-Hannover adult, virgin, castrated rats were randomly divided into two groups, group I (control, n= 20) and group II (tamoxifen, n= 20), receiving 0.5 ml of propylene glycol and 250 mu g of tamoxifen diluted in 0.5 ml of propylene glycol, respectively, daily by gavage for 30 days. On the 31st day, the rats were euthanized and their vaginas were removed and fixed in 10% buffered formalin for the immunohistochemical study of Ki-67 protein expression. Data were analyzed by the Levene and Student's t tests (p<0.05). RESULTS: The mean index of Ki-67 expression in the rat vagina of groups I and II was 4.04 +/- 0.96 and 26.86 +/- 2.19, respectively (p<0.001). CONCLUSIONS: According to the results of the present study, tamoxifen, at the dose and treatment length used, induced a significant increase in the cell proliferation of the vaginal mucosa in castrated rats, as evaluated by Ki-67 protein expression.
Somente Metadadados
Aspectos histomorfométricos do endométrio e do epitélio da mama de ratas castradas, antes e durante o tratamento com estrogênio e com moduladores seletivos dos receptores de estrogênio
(Universidade Federal de São Paulo (UNIFESP), 2001) Zamith, Roberto [UNIFESP]; Baracat, Edmund Chada [UNIFESP]
Somente Metadadados
Avaliação da imunoexpressão do anticorpo monoclonal MIB-1 no epitélio mamário adjacente ao fibroadenoma de mulheres no menacme tratados com tamoxifeno
(Universidade Federal de São Paulo (UNIFESP), 1999) Sousa, Juarez Antônio de [UNIFESP]; Gebrim, Luiz Henrique [UNIFESP]
A quimioprofilaxia do cancer mamario com tamoxifeno tem reduzido em 45 por cento a incidencia de cancer em mulheres de alto risco, segundo dados do National Cancer Institute (l998). Seus efeitos sobre o tecido mamario normal sao pouco conhecidos, bem como sua interacao com os receptores esteroides e a dose-efeito. Estudou-se por tecnica imunohistoquimica, atraves da imunoexpressao do anticorpo monoclonal MIB-1 (IMUNOTECH, catalogo n. 0505, lote OO1), a atividade proliferativa no epitello mamario adjacente ao fibroadenoma de 44 pacientes, de forma aleatoria em duplo-cego, divididas em 3 grupos: A =l6; placebo), B (N=15; tamoxifeno, 10mg) e C (N=13; tamoxifeno, 2Omg). O medicamento foi utilizado por 22 dias, a partir do 20 dia do ciclo menstrual, sendo a cirurgia realizada no 23º dia. O perfil hormonal foi analisado pela dosagem serica de estradiol, progesterona, SHBG (globulina transportadora de horrnonlos esteroides), FSH (horrnonio foliculo-estimulante), LH (honnonlo luteinizante) e prolactina, entre os dias 21 e 24 do ciclo menstrual previo, e no dia da cirurgia. Os grupos B e C apresentaram aumento significante nos niveis de progesterona (p=O,O38), estradiol (p
Somente Metadadados
Avaliação da positividade dos receptores de estrogênio e de progesterona no carcinoma invasivo de mama de mulheres tratadas com tamoxifeno durante dois a catorze dias
(Universidade Federal de São Paulo (UNIFESP), 2004) Uehara, Jorge [UNIFESP]; Gebrim, Luiz Henrique [UNIFESP]
Somente Metadadados
Avaliação histomorfométrica de osso trabecular de ratas em estro-permanente, após o uso de tamoxifeno
(Universidade Federal de São Paulo (UNIFESP), 1996) Simões, Rosana Durães [UNIFESP]; Baracat, Edmund Chada [UNIFESP]
Acesso aberto (Open Access)
Cost-effectiveness of anastrozole, in comparison with tamoxifen, in the adjuvant treatment of early breast cancer in Brazil
(Associação Médica Brasileira, 2009-01-01) Fonseca, Marcelo Cunio Machado [UNIFESP]; Araujo, Gabriela Tannus Branco de [UNIFESP]; Saad, Everardo D.; Universidade Federal de São Paulo (UNIFESP); Axia.Bio Consultoria Econômica; Dendrix Ltda
OBJECTIVE: Breast cancer, a leading type of cancer in many developing countries, is the most frequent non-cutaneous tumor in Brazil. Hormone therapy is the standard of care in the adjuvant treatment of early-stage, hormone-receptor-positive disease, and both tamoxifen and third-generation aromatase inhibitors are options in postmenopausal women. The comparative cost-effectiveness of different treatment strategies is of considerable interest in societies facing limited resources. METHODS: In an attempt to compare cost-effectiveness of upfront treatment with tamoxifen or anastrozole, the medical and economic results in a hypothetical cohort of 64-year-old postmenopausal women, was analyzed considering the Brazilian healthcare system in 2005, the primary perspective of the private sector, and a lifetime horizon. Data from the ATAC Trial, Markov modeling, a modified Delphi panel, and microcosting (in Brazilian R$) were used to estimate costs and effectiveness of the two upfront strategies. RESULTS: The model estimated a gain of 0.55 discounted life-years for patients receiving anastrozole, relative to those treated with tamoxifen. With an incremental cost of R$ 15,141.15, the model estimated that the cost-effectiveness of anastrozole, in relation to tamoxifen, was R$ 27,326.80. Monte Carlo simulations showed that approximately 50% of the cases fell below the threshold of R$ 29,229.00 per life-year gained, which is recommended by the World Health Organization for Brazil. CONCLUSION: It was concluded that upfront anastrozole is a cost-effective option compared with tamoxifen in the adjuvant treatment of postmenopausal women with hormone-receptor-positive early breast cancer.
Acesso aberto (Open Access)
Efeitos de diferentes doses de tamoxifeno sobre a proliferação celular do epitélio mamário
(Federação Brasileira das Sociedades de Ginecologia e Obstetrícia, 2003-04-01) Facina, Gil [UNIFESP]; Baracat, Edmund Chada [UNIFESP]; Lima, Geraldo Rodrigues De [UNIFESP]; Gebrim, Luiz Henrique [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)
PURPOSE: to quantitatively analyze the immunoreaction of monoclonal antibody Ki-67 in the mammary epithelium adjacent to fibroadenoma of premenopausal women treated with tamoxifen, for 50 days, at doses of 5, 10 and 20 mg/day. METHODS: we studied, prospectively, the effects of tamoxifen administered for 50 days, at doses of 5, 10 e 20 mg/day, by the immunoreaction of the Ki-67 (clone Ki-S5) monoclonal antibody on mammary epithelium adjacent to fibroadenoma in premenopausal women. We studied 58 patients in a double-blind trial who were divided into four groups: Group A (n=13; placebo), Group B (n=16; 5 mg/day tamoxifen), Group C (n=14; 10 mg/day) and Group D (n=15; 20 mg/day). All patients received the medication from the first day on of the menstrual cycle and biopsy was performed on the last day of the treatment. Cells stained and not stained by the immunoreagent were counted by optical microscopy (400X) with a digital image capturing system and image analysis. RESULTS: the average percentage of stained nuclei was calculated for all groups: Group A was 2.0 with a standard error (SE) of 0.3. In Group B it was 0.7 (SE=0.2); in Group C it was 0.4 (SE=0,2) and in Group D it was 0.1 (SE=0). Statistical analysis showed significant reductions between the groups (p<0.001), and Tukey's pairwise comparison test confirmed that there was a significant increase in the immunoreaction of the monoclonal Ki-67 antibody in groups B, C and D. CONCLUSIONS: tamoxifen, administered at doses of 5, 10 and 20 mg/day for 50 days, significantly reduced the immunoreaction of monoclonal Ki-67 in the mammary epithelium of premenopausal patients and there was no significant difference between the groups that received 5, 10 and 20 mg/day tamoxifen.
Somente Metadadados
Efeitos do tamoxifeno sobre a expressão da proteína p27 no endométrio de mulheres na pós-menopausa com carcinoma de mama
(Universidade Federal de São Paulo (UNIFESP), 2002) Siufi, Adalberto Abrão [UNIFESP]; Goncalves, Wagner Jose [UNIFESP]
Objetivo: Avaliar a imunoexpressao da proteina p27 no endometrio de pacientes com cancer de mama na pos-menopausa por tecnica imunohistoquimica. Propoe-se a avaliar a influencia do tamoxifeno apos 60 dias sobre a imunoexpressao da p27 no endometrio. Metodo: Estudaram-se, prospectivamente, 53 pacientes com carcinoma de mama, tratadas inicialmente por cirurgia e que receberam 20mg de tamoxifeno por 60 dias. Avaliou-se a expressao da p27 antes e apos o tratamento bem como a imunoexpressao da proteina p27 do material obtido por biopsia endometrial por histeroscopia. Conclusao: O tamoxifeno aumentou, de modo significante, a imunoexpressao da proteina p27 no endometrio de pacientes com cancer de mama na pos-menopausa
Somente Metadadados
Effects of tamoxifen on Doppler velocimetry parameters of periurethral vessels in postmenopausal women
(Springer, 2005-02-01) Faria, Carlos Augusto [UNIFESP]; Sartori, Marair Gracio Ferreira [UNIFESP]; Baracat, Edmund Chada [UNIFESP]; Lima, Geraldo Rodrigues de [UNIFESP]; Girão, Manoel João Batista Castello [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)
The purpose of the present study was to assess the effect of tamoxifen on periurethral vessels by Doppler velocimetry examination. Increase in the number of these vessels as well as decrease in resistance and pulsatility indices by tamoxifen were observed.
Acesso aberto (Open Access)
Eletrorretinograma multifocal em pacientes tratadas com tamoxifeno em baixa dosagem
(Conselho Brasileiro de Oftalmologia, 2004-08-01) Berezovsky, Adriana [UNIFESP]; Salomão, Solange Rios [UNIFESP]; Pereira, Josenilson Martins [UNIFESP]; Sacai, Paula Yuri [UNIFESP]; Chojniak, Márcia Maria Motono; Universidade Federal de São Paulo (UNIFESP); Hospital do Câncer - AC. Camargo
PURPOSE: Tamoxifen, an antiestrogen, has been used as an effective therapeutic agent in the treatment of breast cancer. The drug has been shown to cause ocular toxic effects. The purpose of this study was to determine possible central retinal toxicity by multifocal electroretinograms (mfERGs) in a cohort of patients treated with low-dose tamoxifen (20 mg/day) for breast cancer. METHODS: Multifocal electroretinograms of the central 30 degrees of the retina were obtained of 3 different groups: Experimental group - 15 females (41-59 years, mean 48.6 ± 4.5) with normal fundus, treated with low-dose tamoxifen for 1 to 55 months. Control group - 6 females (30-76 years, mean 49.9 ± 18.8) with previous breast cancer diagnosis who had not received tamoxifen as treatment until ERG testing. Normal control group - 15 normal female volunteers (30-71 years, mean 47.7 ± 12.9). The multifocal amplitude and latency for N1-P1 were measured and statistically analyzed (one-way ANOVA). RESULTS: Mean amplitudes N1-P1 (nV/deg²) were comparable for responses of different eccentricity (0 to 25 degrees). There was no statistically significant difference for implicit time of N1 and P1 (ms) in multifocal electroretinograms between the 3 groups. CONCLUSIONS: Low-dose tamoxifen showed no retinotoxic effect in this small group of women with breast cancer. Follow-up investigation could provide a better understanding of these effects.
Acesso aberto (Open Access)
Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness-a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer
(Biomed Central Ltd, 2013-09-18) Madeira, Marcelo [UNIFESP]; Mattar, Andre [UNIFESP]; Logullo, Angela Flavia [UNIFESP]; Soares, Fernando Augusto; Gebrim, Luiz Henrique [UNIFESP]; Universidade Federal de São Paulo (UNIFESP); Albert Einstein Hosp; Perola Byington Hosp; AC Camargo Hosp
Background: the role of estrogen receptor beta (ER-beta) in breast cancer (BC) remains unclear. Some studies have suggested that ER-beta may oppose the actions of estrogen receptor alpha (ER-alpha), and clinical evidence has indicated that the loss of ER-beta expression is associated with a poor prognosis and resistance to endocrine therapy. the objective of the present study was to determine the role of ER-beta and the ER-alpha/ER-beta ratio in predicting the response to endocrine therapy and whether different regimens have any effect on ER-beta expression levels.Methods: Ninety postmenopausal patients with primary BC were recruited for a short-term double-blinded randomized prospective controlled study. To determine tumor cell proliferation, we measured the expression of Ki67 in tumor biopsy samples taken before and after 26 days of treatment with anastrozole 1 mg/day (N = 25), tamoxifen 20 mg/day (N = 24) or placebo (N = 29) of 78 participants. the pre-and post-samples were placed in tissue microarray blocks and submitted for immunohistochemical assay. Biomarker statuses (ER-beta, ER-alpha and Ki67) were obtained by comparing each immunohistochemical evaluation of the pre- and post-surgery samples using the semi-quantitative Allred's method. Statistical analyses were performed using an ANOVA and Spearman's correlation coefficient tests, with significance at p <= 0.05.Results: the frequency of ER-beta expression did not change after treatment (p = 0.33). There were no significant changes in Ki67 levels in ER-beta-negative cases (p = 0.45), but in the ER-beta-positive cases, the anastrozole (p = 0.01) and tamoxifen groups (p = 0.04) presented a significant reduction in post-treatment Ki67 scores. There was a weak but positive correlation between the ER-alpha and ER-beta expression levels. Only patients with an ER-alpha/ER-beta expression ratio between 1 and 1.5 demonstrated significant differences in Ki67 levels after treatment with anastrozole (p = 0.005) and tamoxifen (p = 0.026).Conclusions: Our results provide additional data that indicate that the measurement of ER-beta in BC patients may help predict tamoxifen and anastrozole responsiveness in the neoadjuvant setting. These effects of hormonal treatment appear to be dependent on the ratio of ER-alpha/ER-beta expression.
Somente Metadadados
Estudo da apoptose no epitélio do lóbulo mamário em mulheres no menacme tratadas com tamoxifeno
(Universidade Federal de São Paulo (UNIFESP), 1999) Gebrim, Luiz Henrique [UNIFESP]
Nosso objetivo foi avaliar, em mulheres no menacme, os efeitos do tamoxifeno administrado durante 22 dias, nas doses de 10 e 20 mg/dia, sobre a morte celular programada (apoptose), no epitelio lobular normal, em tecido adjacente fibroadenomas de mama. Estudaram-se de forma aleatoria em duplo-cego, 40 mulheres com fibroadenoma, eumenorreicas e que nao receberam hormonios nem estiveram gravidas nos ultimos 12 meses. As pacientes foram divididas em tres grupos: Grupo I (n = 14; placebo), Grupo II (n = 13;10 mg/dia) e Grupo III (n =13; 20 mg/dia). Iniciou-se o tratamento no 1§ dia do ciclo menstrual, e as cirurgias for feitas no 22§. Dosaram-se duas vezes o estradiol, progesterona, prolactina, FSH, L e SHBG, sendo a primeira no 22§ dia do ciclo anterior e a segunda no dia da cirurgia O tecido mamario foi fixado em formol a 1O por cento e corado pela HE. Contaram-se o corpusculos apoptoticos utilizando-se microscopio da marca Olympus BX-40, e duplo-cego num total de 10 campos com aumento de 4OOX. O numero medio de corpusculos apoptoticos no Grupo I (controle) foi de 34,8; no Grupo III (1O mg) 12,9 e no Grupo III (20 mg), 12,0. A analise de variancia revelou diferenca estatistica entre os grupos, e o teste de comparacoes multiplas de Fisher confirmou reducao significativa dos corpusculos nos Grupos II e III p < O,OO1. Nao houve diferenca entre os achados dos Grupos II e III. O tamoxifeno, nas doses de 10 e 20 mg/dia, reduziu apos 22 dias de tratamento numero de corpusculos apoptoticos no epitelio do lobulo mamario
Acesso aberto (Open Access)
Estudo da atividade hormonal de mulheres tratadas com tamoxifeno no menacme
(Federação Brasileira das Sociedades de Ginecologia e Obstetrícia, 1998-10-01) Bernardes Jr, Júlio Roberto De M. [UNIFESP]; Gebrim, Luiz Henrique [UNIFESP]; Nazário, Afonso Celso Pinto [UNIFESP]; Kemp, Claudio [UNIFESP]; Lima, Geraldo Rodrigues De [UNIFESP]; Baracat, Edmund Chada [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)
Purpose: to evaluate the effects of tamoxifen (TAM) on plasma levels of estradiol, progesterone, prolactin, luteinizing hormone (LH), follicle-stimulating hormone (FSH) and steroid hormone-binding globulin (SHBG) when given to premenopausal women in the doses of 10 and 20 mg/day for 22 days. Patients and Methods: a randomized double-blind study was performed with 43 premenopausal eumenorrheic women. The patients were divided into three groups: A (N = 15, placebo); B (N = 15, TAM 10 mg/day) and C (N = 13, 20 mg/day). They started taking an oral dose of TAM or placebo on the very first day of the menstrual cycle. Two hormone determinations were performed, both on the 22nd day of the menstrual cycle: the first in the cycle that preceded the use of the drug and the second, in the following cycle, after 22 days of using the medication. We used the Levine and Student tests in order to evaluate the homogeneity of the sample and the variation of the hormone determinations respectively. Results:serum levels of estradiol, progesterone and SHBG increased significantly in groups B and C. In group C, we also observed increase in serum level of FSH (p < 0.0045) and a fall in prolactin level (p < 0.0055). Conclusions: TAM promoted a significant increase in serum concentrations of estradiol, progesterone and SHBG either in the doses of 10 or 20 mg/day. However, significant increase in FSH and decrease in prolactin were obtained only with the dose of 20 mg/day.
Acesso aberto (Open Access)
Estudo da Imunorreação do Anticorpo Monoclonal Ki-67 (MIB-1) e dos Receptores de Estrogênio e Progesterona no Carcinoma de Mama de Mulheres Tratadas com Tamoxifeno em Baixa Dosagem
(Universidade Federal de São Paulo (UNIFESP), 2006-12-31) Sousa, Juarez Antônio de [UNIFESP]; Gebrim, Luiz Henrique [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)
Breast carcinoma is the most common malignancy among women, and it has a major impact on mortality. Studies of primary chemoprevention with tamoxifen have generated high expectations and considerable success rates. The efficacy of lower doses of tamoxifen is similar to that seen with the standard dose of the drug, and there is a reduction in medical care costs and adverse effects. The immune reaction to monoclonal antibody Ki-67 (MIB-1) and the expression of estrogen receptors (1D5) and progesterone receptors (PgR 636) in breast carcinoma were studied in patients treated with 10 mg of tamoxifen for a period of 14 days. A prospective randomized clinical trial was conducted with 38 patients divided into two groups: Group A: N = 20 (control group–without medication) and Group B: N = 18 (tamoxifen/10 mg/day for 14 days). All patients signed an informed consent term previously approved by both institutions (UNIFESP-EPM and Hospital Materno Infantil, Goiânia-GO). Patients underwent incisional biopsy before treatment and 14 days later a sample of tumor tissue was obtained during surgical treatment. Positivity was quantitatively assessed, counting at least 1.000 cells per slide. For statistical data analysis, a Wilcoxon non-parametric test was used, and α was set at 5%. Both groups (A and B) were considered homogeneous regarding control variables. In Group A (control), there was no statistically significant reduction in Ki-67 (MIB-1) (p=0.627), estrogen receptor (1D5) (p=0.296) and progesterone receptor positivity (PgR 636) (p=0.381). In Group B (tamoxifen 10 mg/day), the mean percentage of nuclei stained by Ki- 67 (MIB-1) was 24.7% before and 10.4% after tamoxifen treatment. Mean percentage of nuclei stained by estrogen receptor (1D5) was 59.5% before and 25.9% after tamoxifen treatment. Mean percentage of nuclei stained by progesterone receptor (PgR 636), was 59.3 before and 29.6% after tamoxifen treatment. A statistically significant reduction was found with the three markers (p<0.001). Tamoxifen significantly reduced monoclonal antibody Ki-67 (MIB-1), estrogen receptor (1D5) and progesterone receptor positivity (PgR 636) in the breast epithelium of patients with carcinoma, treated with a 10 mg dose of tamoxifen for 14 days.
Somente Metadadados
Estudo da imunorreação do oncogene Bcl-2 e dos corpúsculos apoptóticos no carccinoma invasivo da mama em mulheres tratadas com tamoxifeno
(Universidade Federal de São Paulo (UNIFESP), 2004) Tanaka, Carlos Itio [UNIFESP]; Gebrim, Luiz Henrique [UNIFESP]
A terapia endócrina do câncer de mama constitui uma das mais importantes formas de seu tratamento. Entretanto, apesar da positividade dos receptores, nem sempre a resposta é favorável. É grande o interesse dos pesquisadores em encontrar marcadores biológicos para avaliar o prognóstico e que também possam predizer as respostas terapêuticas. Estudou-se, prospectivamente, o efeito da terapia endócrina com tamoxifeno (20 mg/dia), em mulheres com câncer de mama invasivo, sobre o índice apoptótico (hematoxilina e eosina) e a imunorreação do anticorpo monoclonal anti-Bcl-2 (Bcl-2 oncoprotein - clone 124). Avaliaram-se, de forma aleatória, 49 pacientes portadoras de carcinoma mamário divididas em três grupos: Grupo A (n = 15; controle), Grupo B (n = 20; tamoxifeno por dois dias) e Grupo C (n = 14; tamoxifeno por 14 dias). Todas a pacientes foram submetidas a biópsia pré e pós-tratamento. Analisou-se o índice apoptótico em 2.000 células por meio de microscopia de luz (400x). A positividade do anticorpo anti-13c1-2 foi avaliada pelo método semi-quantitativo, cujos parâmetros adotados foram a intensidade de coloração da maioria das células coradas e a fração de células neoplásicas mais intensamente coradas. Observou-se aumento significativo do número de corpúsculos apoptóticos nos grupos B (p = 0,001) e C (p = 0,016) após medicação com tamoxifeno (20 mg/dia) por dois e 14 dias, respectivamente. Quanto à imunorreação do anticorpo monoclonal anti-13c1-2, não se comprovou variação significativa nos grupos B (p = 0,063) e C (p = 0,125), antes e após a administração de tamoxifeno (20 mg/dia). Conclui-se que o tamoxifeno aumentou o índice apoptótico com dois e 14 dias de tratamento, enquanto a positividade do Bcl-2 não sofreu variação.
Acesso aberto (Open Access)
Estudo do biomarcador p16 no carcinoma de mama de mulheres submetidas à endocrinoterapia primária de curta duração com tamoxifeno e anastrozol
(Universidade Federal de São Paulo (UNIFESP), 2009-11-25) Melitto, Alexandre Santos [UNIFESP]; Gebrim, Luiz Henrique [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)
Background: Frequent deletions or mutations of the INK4 gene, which encodes the cyclin-dependent kinase 4 inhibitor p16INK4a, have been documented in various human cancers, but little is known about the role of this tumor suppressor gene in primary breast cancer and there is a lack in the literature about its expression behavior in neoadjuvant endocrinetherapy with tamoxifen or anastrozole. Objective: Analysis of p16INK4a expression in patients with invasive ductal carcinomas (IDC) prior to tamoxifen and anastrozole neoadjuvant treatment and possible correlation between predictive and prognostical factors – estrogen receptor (ER), progesterone receptor (PgR). Methods: We examined p16INK4a mRNA expression and its relationship with short period (26 days) neoadjuvant endocrine therapy with tamoxifen and anastrozole in 58 primary breast cancers with palpable ER-positive IDC. They were double-blind randomized in three neoadjuvant treatment groups for 21 days: Anastrozole 1mg/day (n= 17), Placebo (n=25) and Tamoxifen 20mg/day (n=15). Biomarkers status (ER, PgR and p16) were obtained by comparing single immunohistochemical evaluation of pre and post-surgery samples using Allred’s method. Statistical analyses were performed using the SPSS software for Windows. Results: Variation in p16 was 22% to 17% in anastrozole group, 8% to 4% in placebo group and there was no variation in tamoxifen group, standing in 7%. There was no significant statistical diference in p16INK4a expression among the three groups (p=0.17). Variation in p16 was 12% to 9% (p<0.05) when considering the three groups together. There was a significant decrease of p16 expression in pre and post surgery results. There was no significant statistical correlation between p16 expression and hormonal status (RE and RP). Conclusions: There was no significant statistical diference in p16INK4a expression among the three groups. There was a significant statistical decrease in p16INK4a expression when compared pre and post surgery values. These findings could indicate that expression of p16 and variation in pre and post surgery samples are associated with hormone responsiveness and mechanisms of resistance. There were no significant statistical correlation between p16 expression and hormonal status (RE and RP). Further studies are necessary to understand their functional interrelationships and whether high p16INK4a expression may be associated with a lack of hormone responsiveness in breast cancer.
Somente Metadadados
Estudo morfométrico do epitélio mamário normal de mulheres medicadas com tamoxifeno na fase lútea do ciclo menstrual
(Universidade Federal de São Paulo (UNIFESP), 1996) Uehara, Jorge [UNIFESP]; Gebrim, Luiz Henrique [UNIFESP]
Somente Metadadados
Polymorphism of the cyp2d6 gene in women with breast cancer treated with tamoxifen
(Associacao Brasileira Pesquisa Pos-Graduacao Fisioterapia-Abrapg-Ft, 2016) de Vasconcelos-Valenca, R. J.; Melo, M. A.; Lima, E. M.; de Sousa, G. V.; Nazario, A. C. [UNIFESP]; da Silva, B. B.
Objective: To evaluate polymorphism frequency of the CYP2D6*4, *10, and *17 alleles in women with breast cancer treated with tamoxifen. Materials and Methods: Ninety-five women with estrogen and progesterone receptor-positive breast carcinoma were investigated from September to December 2013. A three-ml sample of peripheral blood was collected from each patient to analyze the presence of CYP2D6*4, *10, and *17 allele polymorphism by specific polymerase chain reaction technique (PCR) for analysis of haplotypes *1, *4, *10, and *17, determined by studies of different single-nucleotide polymorphism (SNP). The data obtained were compiled and analyzed with the aid of Excel software 2010. Results: The frequency of CYP2D6 alleles *4, *10, and *17 was 16%, 29%, and 2%, respectively, and haplotype *1/*10 was shown in 22% of the women. The phenotype of intermediate metabolism occurred in 8% of women. Conclusions: The present study showed a deficiency in tamoxifen metabolism, characterized by intermediate metabolism in 8% of Brazilian women.
Restrito
Relação do tamoxifeno e tromboembolismo venoso profundo na intervenção cirúrgica de reconstrução de mama - revisão de literatura
(Universidade Federal de São Paulo, 2022-02-10) Malagutti, Anna Carolina [UNIFESP]; Crozatti, Márcia Terezinha Lonardoni [UNIFESP]; http://lattes.cnpq.br/7164068307075233
O câncer de mama se tornou o mais diagnosticado no mundo nas mulheres, sendo mais prevalente o que expressa receptor de hormônio. Como consequência um maior número de mulheres passou a usar o tamoxifeno como terapia adjuvante. Entretanto, alguns estudos apontam aumento de probabilidade de eventos tromboembólicos na vigência deste tratamento. A reconstrução de mama é uma cirurgia frequentemente realizada em pacientes com essa condição, e as complicações do uso de tamoxifeno nessa cirurgia podem levar a trombose, isquemia até necrose e possibilidade de perda parcial ou total do retalho. É importante estudar a relação do tamoxifeno com o tromboembolismo venoso profundo na intervenção cirúrgica de reconstrução de mama de modo a subsidiar a construção de um possível algoritmo e assim melhorar o desfecho cirúrgico. Esta relação foi estudada através de revisão da literatura. A metodologia se baseou na técnica “P.I.C.O” para formulação da estratégia de busca, utilizando a base de dados Pubmed. Foram selecionados 6 artigos, dentre os quais apenas um mostra a relação do tamoxifeno com o tromboembolismo na reconstrução de mama. Porém, os artigos apontam a necessidade de estudos mais robustos sobre o assunto, com maior amostragem, melhor capacidade de relacionar o tipo de reconstrução com o tromboembolismo e sugerem a necessidade de realizar a pausa do medicamento antes e após a cirurgia de reconstrução de mama.
Somente Metadadados
Retinal function in patients treated with tamoxifen
(Springer, 2010-04-01) Song Watanabe, Sung Eun [UNIFESP]; Berezovsky, Adriana [UNIFESP]; Motono, Marcia [UNIFESP]; Sacai, Paula Yuri [UNIFESP]; Pereira, Josenilson Martins [UNIFESP]; Sallum, Juliana Maria Ferraz [UNIFESP]; Gebrim, Luiz Henrique [UNIFESP]; Salomão, Solange Rios [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)
Tamoxifen, an effective treatment of breast cancer, has been shown to cause ocular toxic effects. the purpose of this study was to determine retinal toxicity by full-field and focal electroretinograms (ERGs) in patients treated with tamoxifen. Full-field and focal ERGs were obtained from three groups: Tamoxifen-14 females (47-72 years, mean 58.3 +/- A 9.1) with normal fundus, treated with tamoxifen from 2 to 37 months; No Treatment-10 females (39-65 years, mean 50.1 +/- A 8.7) with previous breast cancer diagnosis and before tamoxifen treatment; Control-13 normal female volunteers (41-81 years, mean 52.7 +/- A 12.1). Peak-to-peak amplitude and b-wave implicit time were measured and statistically analyzed. Mean peak-to-peak amplitudes and implicit time from full-field and focal ERGs were comparable for the three different groups. Low-dosage tamoxifen showed no retinotoxic effect assessed by full-field and focal ERG in this small group of women with breast cancer.

Navegando por Palavras-chave "Tamoxifen"

Resultados por página

Opções de Ordenação